Evidence map›Paper›PMID 41708603›Full record

ArticleNature communications2026

cGAS-IFN-I responses by extracting nuclear DNA from dying cells via nucleocytosis.

Hideo Negishi, Yusuke Wada, Yoshitaka Shirasaki, Tomoya Hayashi, Yuji Kubota, Tomio Iwasaki, Mina Kurosawa, Tatsuma Ban, Daisuke Muto, Yusuke Suenaga and 20 more

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

Hideo Negishi *Division of Vaccine Science, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan. hnegishi@ims.u-tokyo.ac.jp.ORCID http://orcid.org/0009-0006-4571-2476
Yusuke Wada *Division of Vaccine Science, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.ORCID http://orcid.org/0009-0000-7956-8085
Yoshitaka Shirasaki *Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan.ORCID http://orcid.org/0000-0002-3808-1630
Tomoya HayashiDivision of Vaccine Science, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Yuji KubotaDivision of Cell Signaling and Molecular Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Tomio IwasakiResearch and Development Group, Hitachi, Ltd., Ibaraki, Japan.ORCID http://orcid.org/0009-0004-1800-4234
Mina KurosawaDivision of Vaccine Science, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Tatsuma BanDepartment of Immunology, Yokohama City University Graduate School of Medicine, Kanagawa, Japan.ORCID http://orcid.org/0000-0001-9517-9661
Daisuke MutoLaboratory of Evolutionary Oncology, Chiba Cancer Center Research Institute, Chiba, Japan.
Yusuke SuenagaLaboratory of Evolutionary Oncology, Chiba Cancer Center Research Institute, Chiba, Japan.ORCID http://orcid.org/0000-0001-6902-5386
Taichi KojimaDivision of Vaccine Science, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Yuzuki MatsudaDivision of Vaccine Science, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Sean Lord IrishDivision of Vaccine Science, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Kosuke DodoSynthetic Organic Chemistry Laboratory, RIKEN Cluster for Pioneering Research, Saitama, Japan.ORCID http://orcid.org/0000-0001-6008-2915
Toru SuzukiDivision of RNA and gene regulation, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.ORCID http://orcid.org/0000-0003-1864-8027
Mai YamagishiLive Cell Diagnosis, Ltd., Saitama, Japan.ORCID http://orcid.org/0000-0002-4449-5899
Burcu TemizozDivision of Vaccine Science, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Atsushi YoshimoriInstitute for Theoretical Medicine, Inc., Kanagawa, Japan.ORCID http://orcid.org/0000-0003-3206-5143
Chisato KanaiINTAGE Healthcare, Inc., Osaka, Japan.
Yoji NagasakiDepartment of Infectious Diseases, NHO Kyushu Medical Center, Fukuoka, Japan.
Masaki OhmurayaDepartment of Genetics, School of Medicine, Hyogo Medical University, Hyogo, Japan.
Tomohiko TamuraDepartment of Immunology, Yokohama City University Graduate School of Medicine, Kanagawa, Japan.ORCID http://orcid.org/0000-0002-9664-1747
Atsushi IwamaThe University of Tokyo Pandemic Preparedness, Infection and Advanced Research Center (UTOPIA), The University of Tokyo, Tokyo, Japan.ORCID http://orcid.org/0000-0001-9410-8992
Toshifumi InadaThe University of Tokyo Pandemic Preparedness, Infection and Advanced Research Center (UTOPIA), The University of Tokyo, Tokyo, Japan.ORCID http://orcid.org/0000-0002-2695-588X
Etsushi KurodaDepartment of Immunology, Hyogo Medical University School of Medicine, Hyogo, Japan.
Kouji KobiyamaDivision of Vaccine Science, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.ORCID http://orcid.org/0000-0002-5846-4807
Noriko Toyama-SorimachiInternational Vaccine Design Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.ORCID http://orcid.org/0000-0003-3474-0456
Mutsuhiro TakekawaThe University of Tokyo Pandemic Preparedness, Infection and Advanced Research Center (UTOPIA), The University of Tokyo, Tokyo, Japan.ORCID http://orcid.org/0000-0002-8027-3847
Cevayir CobanInternational Vaccine Design Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.ORCID http://orcid.org/0000-0002-4467-7799
Ken J IshiiDivision of Vaccine Science, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan. kenishii@ims.u-tokyo.ac.jp.ORCID http://orcid.org/0000-0002-6728-3872

Funding

Japan Agency for Medical Research and Development (AMED) 24gm4010025h0001Japan Agency for Medical Research and Development (AMED) JP223fa727001Japan Agency for Medical Research and Development (AMED) JP223fa727002MEXT | JST | Core Research for Evolutional Science and Technology (CREST) JPMJCR18H1
6 · The paper itself

Abstract

Self-DNA triggers cGAS-STING-mediated type I interferon (IFN-I) to induce both protective and pathogenic immune responses; however, how self-DNA activates the cytosolic cGAS-STING pathway remains unclear. Here we show that the cGAS/STING/IFN-I axis is activated by self-DNA via a process termed 'nucleocytosis', in which nuclear DNA is extracted from dying cells by macrophages. Mechanistically, lysosomal malfunction, via both proton loss and palmitoyl-protein thioesterase 1 (PPT1) inhibition, triggers cell death and calreticulin accumulation in the nuclei. Live-cell imaging of secretion activity reveals that macrophages access the calreticulin-enriched nuclei of dying cells and extract DNA for cGAS-STING activation. Consistent with these findings, PPT1-targeting cationic amphiphilic drugs induce a cGAS-STING-dependent IFN-I response in vitro and in vivo. Our findings thus identify nucleocytosis as a macrophage function for nuclear DNA extraction and induction of the cGAS/IFN-I axis, and suggest that nucleocytosis-inducing cell death could be a druggable target for treating self-DNA-related inflammatory diseases.

Indexed as

Cell NucleusDNAInterferon Type INucleotidyltransferasesAnimalsCalreticulinCell DeathcGAS-STING Signaling PathwayCyclic Guanosine Monophosphate-Adenosine Monophosphate SynthaseHumansMacrophagesMembrane ProteinsMiceMice, Inbred C57BLSTING ProteinCalreticulincGAS protein, humancGAS protein, mouseCyclic Guanosine Monophosphate-Adenosine Monophosphate SynthaseDNAInterferon Type IMembrane ProteinsNucleotidyltransferasesSting1 protein, mouseSTING Protein

Identifiers

PMID41708603
PMCPMC12917151

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.